Clean air for Pharmaxis

By Dylan Bushell-Embling
Wednesday, 13 August, 2008

Results from the Phase II clinical trial of Pharmaxis' [ASX: PXS] Bronchitol treatment in cystic fibrosis patients have produced promising results.

The study showed that Bronchitol was able to improve lung function in cystic fibrosis sufferers, as measured by forced vital capacity and FEV1 - the amount of air that can be forcibly exhaled in one second.

Improvements in lung function were dose-dependant, with the best results occurring in the patients which had received the highest dose. Pharmaxis has concluded that 400mg is the optimal Bronchitol dose.

Bronchitol is designed to hydrate the airway surface, improve lung hygiene and promote normal lung clearance. It is a proprietary formulation of mannitol, administered as a dry powder through a hand-held inhaler.

Related News

Indigenous-led initiative to resurrect the South Island Giant Moa

New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...

Abnormal brain protein targeted in Parkinson's study

Researchers have identified a new brain protein involved in the development of Parkinson's...

Epilepsy disease model treated in a laboratory dish

A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd